ADAG earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -7.59. Updated 2026-07-23.
Adagene (ADAG) Research Hub
Adagene (ADAG) trades on NASDAQ, CN in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.4 USD (+3.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.59, market cap 0.13B. This hub links to the full technical, earnings and options research available for ADAG.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CN |
| Last close | 3.4 USD (+3.98%) |
| 52-week range | 3.17 USD – 4.78 USD |
| Trend regime | Range |
| 14-day RSI | 31.6 (Bearish) |
| Trailing P/E | -7.59 |
| Market cap | 0.13B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for ADAG
Covered Call on ADAG: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADAG: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADAG: how it works, illustrative setup around the real 3.4 USD price, max profit/loss, breakeven and when to use it. Educational.
ADAG technical analysis: range, last 3.4 USD, RSI 31.6, 52w range 3.17 USD–4.78 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ADAG in?
Adagene (ADAG) is classified under Healthcare (Biotechnology), listed on NASDAQ, CN.
Is ADAG in an uptrend or downtrend?
As of 2026-09-11, ADAG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADAG's trailing P/E ratio?
ADAG's trailing P/E is -7.59, with a market cap of 0.13B. See the earnings research page for full valuation detail.
When does ADAG next report earnings?
ADAG is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.22 USD.